Skip to main content
STADA Arzneimittel AG logo

STADA Arzneimittel AG — Investor Relations & Filings

Ticker · SAZ ISIN · DE0007251803 LEI · 529900FMTTLMH0P0DL10 HM Manufacturing
Open in API
Filings indexed 916 across all filing types
Latest filing 2014-03-25 Report Publication Anno…
Country DE Germany
Listing HM SAZ

About STADA Arzneimittel AG

https://www.stada.com/

STADA Arzneimittel AG is a pharmaceutical company that operates on a three-pillar strategy consisting of generics, consumer healthcare products, and specialty pharmaceuticals. The company is a leading manufacturer of affordable generic medicines, which have been a core part of its business since its founding. In the consumer healthcare segment, STADA markets a wide portfolio of over-the-counter (OTC) products and well-known brands. The specialty pharmaceuticals division focuses on developing and marketing value-added medicines, including an expanding portfolio of biosimilars for therapeutic areas such as oncology, immunology, and bone health.

Recent filings

Filing Released Lang Actions
Datum:25.03.2014
Report Publication Announcement Classification · 100% confidence The document is a short notification (under 5,000 characters) that explicitly states the availability of a financial report ('Hinweis auf Halbjahresfinanzbericht') and provides a URL to access it. According to the 'Menu vs Meal' rule, this is an announcement of a report rather than the report itself, making it a Report Publication Announcement (RPA).
2014-03-25 German
STADA Arzneimittel AG: Successful financial year 2013 - Adjusted EBITDA reaches new record high - Dividend to increase by 32 percent - 2014 outlook adjusted
Earnings Release Classification · 100% confidence The document is an 'Ad-hoc' announcement dated March 24, 2014, detailing the 'Successful financial year 2013' results, including record Adjusted EBITDA, Group sales figures, dividend increase proposal, and the 2014 outlook adjustment. This content—a summary of key financial highlights for a completed period—is characteristic of an Earnings Release (ER). Although it contains detailed figures, it is presented as an immediate, high-level announcement ('Ad hoc announcement according to § 15 WpHG') rather than the comprehensive, formal Annual Report (10-K) or a detailed Interim Report (IR). It is not a transcript (CT), a presentation (IP), or a formal audit report (AR). FY 2013
2014-03-24 English
Declaration of Voting Results & Voting Rights Announcements 2014
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and details changes in the percentage of voting rights held by Gryphon International Investment Corporation and Gryphon Investment Counsel Inc. in STADA Arzneimittel AG, referencing German Securities Trading Act (WpHG) sections 21 and 22. This directly corresponds to the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document length is short (approx. 2500 chars), but its content is the announcement itself, not a notice about another report, making DVA the most specific fit over the general RPA or RNS.
2014-03-06 English
Declaration of Voting Results & Voting Rights Announcements 2014
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Voting Rights Announcements' and explicitly states 'Veröffentlichung einer Stimmrechtsmitteilung' (Publication of a voting rights notification). It details a notification received from Allianz Global Investors Europe GmbH regarding their voting stake falling below the 3% threshold, citing German Securities Trading Act (§ 21 Abs. 1 Satz 1 WpHG). This directly corresponds to the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA), which covers official results from shareholder votes or, in this context, significant changes in voting rights ownership.
2014-03-05 German
STADA Arzneimittel AG: Preliminary figures show successful financial year 2013 - Dividend to increase by 32 percent - Outlook for 2014 confirmed
Earnings Release Classification · 100% confidence The document is titled 'Ad-hoc' and dated March 3, 2014. It announces 'Preliminary figures show successful financial year 2013' and provides key financial highlights (sales, EBITDA, net income, EPS) for the past year, along with a confirmation of the outlook for 2014. Crucially, it states, 'STADA will publish its final figures for financial year 2013 on March 27, 2014.' This structure—announcing preliminary results and key metrics before the final report release—is characteristic of an Earnings Release (ER). It is not the full Annual Report (10-K) or the comprehensive Interim Report (IR), but the initial, high-level announcement of period results. FY 2013
2014-03-03 English
STADA Arzneimittel AG: Successfully concluded purchase of the Russian branded product portfolio Aqualor(R) for the self-medication of sinusitis and sore throat
Regulatory Filings Classification · 100% confidence The document is an 'Ad-hoc' announcement dated February 28, 2014, detailing the successful conclusion of a purchase (acquisition of a product portfolio). It is short (2143 characters) and reports a specific corporate event (M&A activity) that is not a standard periodic report (like 10-K or IR) or a general announcement of a report release (RPA). Since the event is a merger/acquisition/takeover activity, the most fitting category is 'M&A Activity' (TAR). It is not a general regulatory filing (RNS) because a more specific category exists.
2014-02-28 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.